指南与共识姑息放疗与转移瘤放疗物理与技术

新冠疫情期间发布的放疗分次方案:证据质量系统综述及未来建议

Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2020-08-11

该系统综述评估了新冠疫情期间54篇出版物中233个推荐的分次方案,由20名专家按14个疾病组对常规方案和疫情推荐方案进行证据质量分级。结果显示,治愈性和姑息性推荐方案的证据质量均显著下降,治愈性方案高质量证据从51.4%降至4.8%,专家意见从5.6%升至49.3%。

要点

  • 疫情推荐的分次方案证据质量显著低于常规最高质量方案。
  • 治愈性方案高质量证据占比从51.4%降至4.8%。
  • 各疾病部位和适应症的证据质量下降幅度存在差异。

核心结论

  • 疫情期间大量推荐的低分次放疗方案所依据的证据质量低于常规使用的最高质量分次方案。

研究设计与样本

  • 基于对新冠疫情期间剂量分次推荐方案的系统综述,20名专家组成员分配至14个疾病组,对每种情况常规使用的最高质量方案和所有疫情推荐方案进行命名和分级,采用美国放射肿瘤学会质量证据标准进行评级。

主要发现

  • 2020年1月至5月共纳入54篇相关出版物,包含233个推荐的新冠适应分次方案。
  • 部位特异性治愈性和姑息性推荐方案均显著从已确立的高质量证据转向低质量证据和专家意见(P = .022 和 P < .001)。
  • 治愈性方案中,高质量证据占比从疫情前的51.4%降至疫情中的4.8%,专家意见从5.6%升至49.3%,但不同疾病部位和具体适应症的变化幅度存在差异。

关键数值与推荐

  • 采用美国放射肿瘤学会质量证据标准对方案进行分级。
  • 治愈性方案高质量证据占比疫情前51.4% vs 疫情中4.8%,专家意见5.6% vs 49.3%。

临床怎么用

  • 为临床医生在疫情等特殊情况下个体化决策和患者咨询提供基于证据的评估依据。
  • 数据可用于支持大流行第二波或新区域激增时的放疗实践。

局限性

  • 系统综述仅基于2020年1月至5月发表的54篇文献,证据质量评级依赖专家共识。
  • 不同疾病部位和适应症的证据质量变化幅度存在差异,未逐一列出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Numerous publications during the COVID-19 pandemic recommended the use of hypofractionated radiation therapy. This project assessed aggregate changes in the quality of the evidence supporting these schedules to establish a comprehensive evidence base for future reference and highlight aspects for future study. METHODS AND MATERIALS: Based on a systematic review of published recommendations related to dose fractionation during the COVID-19 pandemic, 20 expert panelists assigned to 14 disease groups named and graded the highest quality of evidence schedule(s) used routinely for each condition and also graded all COVID-era recommended schedules. The American Society for Radiation Oncology quality of evidence criteria were used to rank the schedules. Process-related statistics and changes in distributions of quality ratings of the highest-rated versus recommended COVID-19 era schedules were described by disease groups and for specific clinical scenarios. RESULTS: From January to May 2020 there were 54 relevant publications, including 233 recommended COVID-19-adapted dose fractionations. For site-specific curative and site-specific palliative schedules, there was a significant shift from established higher-quality evidence to lower-quality evidence and expert opinions for the recommended schedules (P = .022 and P < .001, respectively). For curative-intent schedules, the distribution of quality scores was essentially reversed (highest levels of evidence "pre-COVID" vs "in-COVID": high quality, 51.4% vs 4.8%; expert opinion, 5.6% vs 49.3%), although there was variation in the magnitude of shifts between disease sites and among specific indications. CONCLUSIONS: A large number of publications recommended hypofractionated radiation therapy schedules across numerous major disease sites during the COVID-19 pandemic, which were supported by a lower quality of evidence than the highest-quality routinely used dose fractionation schedules. This work provides an evidence-based assessment of these potentially practice-changing recommendations and informs individualized decision-making and counseling of patients. These data could also be used to support radiation therapy practices in the event of second waves or surges of the pandemic in new regions of the world.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Thomson DJ, Yom SS, Saeed H, et al. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. Int J Radiat Oncol Biol Phys. 2020. PMID: 32798063. doi:10.1016/j.ijrobp.2020.06.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。